although sales in the Ophthalmic Devices segment missed expectations in Q4, the fourth consecutive quarter of double-digit growth in the Microsurgery division ensured that FY17/18 revenue targets were met. Moreover, robust operational leverage in Microsurgery and a favourable product mix in Ophthalmic Devices took the adjusted operating margin towards the higher end of the guidance range for FY17/18. Given the strong traction for newer products in both the businesses, we expect the positive g
07 Dec 2018
Microsurgery leads the pack in Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Microsurgery leads the pack in Q4
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
07 Dec 2018 -
Author:
Sumit Sayal -
Pages:
3
although sales in the Ophthalmic Devices segment missed expectations in Q4, the fourth consecutive quarter of double-digit growth in the Microsurgery division ensured that FY17/18 revenue targets were met. Moreover, robust operational leverage in Microsurgery and a favourable product mix in Ophthalmic Devices took the adjusted operating margin towards the higher end of the guidance range for FY17/18. Given the strong traction for newer products in both the businesses, we expect the positive g